Northern Health’s Physician Quality Improvement program has a brand new podcast - Qualitycast North hosted by Dr. Shyr Chui!
Newsroom
The Change: Due to provincial changes in hazardous drug handling, NH is changing to methotrexate PFS formats for ectopic pregnancy treatment. This change enables staff to provide a ready-to-administer dose of methotrexate.
Resolution: Availability of famotidine 10 mg/mL X 2 mL injectable has stabilized and NH pharmacy has adequate stock to support usual usage across the health region.
The Issue: Sodium phosphate 3 mmol/mL injection continues to be available in limited quantities only (reduced monthly order allocation). NH has approximately 2 to 3 weeks of supply between current pharmacy stock and stock available in patient care areas.
Due to changes in hazardous drug handling throughout British Columbia, Northern Health is transitioning to a methotrexate pre-filled syringe (PFS) format at select sites.
The Issue: Sanofi has been unable to provide adequate order volumes of some formats of enoxaparin (Lovenox®) to meet usage requirements across NH. However, three biosimilar enoxaparin products are now available in Canada and on formulary (Noromby™, Redesca®, and Inclunox®).